论文部分内容阅读
目的探讨联合检测血清CEA、CA153和CYFRA21-1对乳腺癌的临床诊断价值。方法采用电化学发光技术(CLIA)检测乳腺癌54例(乳腺癌组)、乳腺良性疾病38例(乳腺良性疾病组)及同期健康体检正常的40例(健康对照组)血清CEA、CA153和CYFRA21-1水平,并进行比较分析。结果乳腺癌组血清CEA、CA153和CYFRA21-1水平、阳性率及3项联合检测的阳性率均高于健康对照组及乳腺良性疾病组,差异有统计学意义(P<0.05);乳腺癌组CEA、CA153和CYFRA21-1单项检测的敏感性分别为37.0%、64.8%、59.2%,三项联合检测的敏感性为85.2%,CEA、CA153和CYFRA21-1单独检测与三项联合检测的敏感性比较差异有统计学意义(P<0.05)。结论联合检测血清CEA、CA153和CYFRA21-1可提高乳腺癌诊断的敏感性,对乳腺癌的早期诊断有十分重要的价值。
Objective To investigate the clinical value of combined detection of serum CEA, CA153 and CYFRA21-1 in breast cancer. Methods Serum levels of CEA, CA153 and CYFRA21 were detected by CLIA in 54 cases of breast cancer (breast cancer group), 38 cases of benign breast disease (benign breast disease group) and 40 healthy controls (healthy control group) -1 level, and comparative analysis. Results The positive rates of CEA, CA153 and CYFRA21-1 in breast cancer group were significantly higher than those in healthy control group and benign breast disease group (P <0.05). The positive rates of CEA, CA153 and CYFRA21-1 in breast cancer group were significantly higher than those in healthy control group and benign breast disease group The sensitivities of single detection of CEA, CA153 and CYFRA21-1 were 37.0%, 64.8% and 59.2% respectively. The sensitivity of the three combined tests was 85.2%. The sensitivity of CEA, CA153 and CYFRA21-1 alone and three combined tests The difference was statistically significant (P <0.05). Conclusion The combined detection of serum CEA, CA153 and CYFRA21-1 can improve the sensitivity of breast cancer diagnosis, which is of great value in the early diagnosis of breast cancer.